Expert decision support software for predicting the metabolic fate of chemicals in mammals.

Similar documents
Expert decision support software for predicting the forced degradation pathways of organic compounds

Scientifically Robust. Expert Software. Improving efficiency and aiding regulatory submission for over 30 years

Predicting Metabolites

Predicting Metabolites

Mutagenic impurities: predicting alerting structures using in silico tools

Sarah Nexus: Strain Information

Use of (Q)SAR to Evaluate Potential Genotoxic Impurities

Nexus 2.2: Overview. Dr Nicholas Marchetti Product Manager Dr Adrian Fowkes Senior Scientist

In silico strategies to assess potentially mutagenic impurities under ICH M7

The use of integrated in silico solutions under the proposed ICH M7 guidelines

Thermo Scientific Compound Discoverer Software. Integrated solutions. for small molecule research

Metabolite Identification Workflows: A Flexible Approach to Data Analysis and Reporting

In silico strategies to assess potentially mutagenic impurities under ICH M7

Generics Perspective: Success Strategies for Genotoxic Impurity Identification, Assessment and Control

Acceptable Intake (AI) and Permitted Daily Exposure (PDE) Data Sharing Project for Pharmaceutical Impurities

Leadscope Model Applier and the ICH M7 Impurities Guidelines Frequently Asked Questions

How discovery activities can influence metabolic profiling in the regulatory space? C. DELATOUR EBF, 25 th September 2015

MRC-NIHR National Phenome Centre

Lhasa Limited Collaborative Data & Knowledge Sharing

Evaluation of (Q)SAR models for the prediction of mutagenicity potential

How to bring your registration dossier in compliance with REACH Tips and Hints - Part 5

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Printed paper and board: Priority setting strategy for toxicological assessment

Metabolite ID. Introduction

CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT.

Agilent Solutions for Metabolomics YOUR PATH TO SUCCESS

DRAGON DATABASE OF GENES ASSOCIATED WITH PROSTATE CANCER (DDPC) Monique Maqungo

Simultaneous in vivo Quantification and Metabolite Identification of Plasma Samples Using High Resolution QTof and Routine MS E Data Analysis

Cosmetics Europe LRSS Programme

QSAR and Read-Across Approaches using in silico Tools in Food Ingredient/Contaminant Safety Assessments at the U.S. Food & Drug Administration

Using WinNonlin with UNIFI: Enhanced Export for the Metabolite Identification Application Solution

Pharmaceutical LC/MS Solutions from Agilent Technologies

MetaboScape 2.0. Innovation with Integrity. Quickly Discover Metabolite Biomarkers and Use Pathway Mapping to Set them in a Biological Context

ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie)

ENGAGE. Helping you manage your investment planning process, all in one place, from a trusted source of fund, product and platform information

ENGAGE. Manage your investment planning process all in one place

Agilent Solutions for Metabolomics EMERGING INSIGHTS

QSAR APPLICATION TOOLBOX, v 4.1 BASIC PRACTICAL TRAINING WORKSHOP. BARCELONA, SPAIN November, 2017 AGENDA

2017 AAM CMC Workshop

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase

BNZ is New Zealand s third largest financial institution. Established in 1861, and a subsidiary of National Australia Bank since 1992, BNZ employs

Safety Qualification Process and Application of Thresholds. Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm

Extending the small molecule similarity principle to all levels of biology

DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION

Agilent s NEW MassHunter Profinder

NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS. Cutting-Edge Science and Constant Innovation: The Keys to Success

UNIFI: an innovative enabling platform Ken Eglinton Nordic User Training, September 2013

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)

How to Manage Metabolite Profiling Requests, the CRO Perspective. Dr Martha A Green Manager Qualitative Mass Spectrometry Charles River, Edinburgh

ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk

The Challenges of Decision Making Using Uncertain Data

M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk

inventivhealthclinical.com The Goal: Reducing Uncertainty A Word on RBM

Services and Support. System design. Hardware. Installation. Peace of mind. Digital Signage

FROM DISCOVERY TO INSIGHT

RAAF Appendix ENV-E: Scenario 5 1 (44)

As our brand migration will be gradual, you will see traces of our past through documentation, videos, and digital platforms.

Informatics and High Resolution QTof MS. How can we ask better questions and get better answers in DMPK? Mark D. Wrona

Impact factor: 3.958/ICV: 4.10 ISSN:

Integrating Molecular Toxicology Earlier in the Drug Development Process

dixa-a data infrastructure for chemical safety Jos Kleinjans Dept of Toxicogenomics Maastricht University

A ROBUST, COMPLIANT AND EFFICIENT ADVICE PROCESS A LOOK AT THE SIMPLYBIZ GROUP APPROACH

Advancing Information Management and Analysis with Entity Resolution. Whitepaper ADVANCING INFORMATION MANAGEMENT AND ANALYSIS WITH ENTITY RESOLUTION

Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances

Toxicological studies of impurities and degradation products: in silico Methodologies as a safety assessment tool

Directly integrated in your planning software, it gives you suggestions for products that are perfectly suited to your building project.

ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances

Introduction and Overview of a Biological Pathway-Based Approach to Disease and Drug Discovery

Guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products

BIOANALYTICAL STRATEGY FOR IN VITRO METABOLITE SCREENING WITH EXACT MASS USING THE Q-Tof micro. Jose M. Castro-Perez 1, Carina Leandersson 2

THE SYSTEMATIC REVIEW OF MECHANISTIC DATA IN IRIS ASSESSMENTS

D360 Self-Service Data Access and Integration Benefits. David Lowis D. Phil. Senior Director, Product Management

Drug Discovery and Development PHG 311. Prof. Dr. Amani S. Awaad

DEVON AND CORNWALL POLICE

At the heart of your advice

Audit Sampling With MindBridge. Written by: Corey Yanofsky and Behzad Nikzad

Why Test Management? 2 TechExcel DevTest

The WHO Framework for Combined Exposures and MOA/AOP Analysis; Implications for Euromix. Euromix Kick Off Meeting

Progress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies

How to write a logframe

Quality Management System Guidance. ISO 9001:2015 Clause-by-clause Interpretation

Tox21: Opportunities& Challenges. Richard A. Becker Ph.D., DABT American Chemistry Council

Sage 200c Business Intelligence Datasheet

The Cost Effectiveness of Employment Support for People with Disabilities 1

Saville Consulting Assessment Suite

PHARMACEUTICAL TESTING

The Need for Scientific. Data Annotation. Alick K Law, Ph.D., M.B.A. Marketing Manager IBM Life Sciences.

Predictive Coding Defensibility: The Symantec Transparent Predictive Coding Workflow

Invoice Status Service

CHOOSING AN AWARDING ORGANISATION

Cintra iq Implementation Methodology (C.I.M) Document for public distribution

Smart India Hackathon

PROUS SCIENCE INTEGRITY

Oracle Knowledge Analytics User Guide

Improving Productivity with Applied Biosystems GPS Explorer

Comments on Key Performance Indicators ( KPI ) Matrix and Statistical Validity

Consultation on proposals for a new Cancer Drugs Fund (CDF) operating model: Q&A

Technical Notes for Guidance. on the assessment of technical equivalence of substances regulated under Directive 98/8/EC

INTELLIGENCE & CYBER SECURITY WEBINT MODULAR SOLUTIONS

Transcription:

Expert decision support software for predicting the metabolic fate of chemicals in mammals.

Index P3 P4-5 P6 P7 P8 Introduction to Meteor Nexus Meteor Nexus is the expert knowledge-based software for the prediction of metabolic fate in animals. Features and benefits Including features such as intuitive filtering, SMARTCyp modelling and customisable reports, Meteor provides transparent and scientifically robust predicitons. How Meteor Nexus works Drawing on a wealth of scientific experience, Lhasa has developed three prediction methodologies for assessing the likelihood of a predicted metabolite. Why choose Lhasa? Lhasa has been creating scientifically robust expert software to improve efficiency and aid regulatory submission for over 30 years. Our products Lhasa develops software for toxicity, metabolic fate, purge factor calculation and chemical degradation.

Introduction to Meteor Nexus Meteor Nexus is the expert knowledge-based software for the prediction of metabolic fate in mammals. Using structure activity relationship (SAR) analysis, Lhasa s scientific experts have developed a comprehensive dictionary of biotransformations covering both phase 1 and phase 2 metabolism. Offering 3 different prediction methodologies, predictions given by Meteor are supported by a level of likelihood, graphical representation of the biotransformation, mechanistic rationale, metabolism data of real compounds and key references. These highly transparent and scientifically robust predictions provide the right level of information to support a thorough review by experts. Drawing on over 30 years of experience, Lhasa Limited s scientists continually work on the Meteor knowledge base, updating it regularly with current metabolism knowledge. They use their expertise to analyse complex, sometimes conflicting data and provide expert reasoning rules to give you an indication of how compounds are likely to be metabolised. The expert predictions made by Meteor are underpinned by high-quality data describing parent compounds, their experimentally seen metabolites and the biotransformations that occurred. This data has been curated by expert Lhasa scientists and currently comprises more than 2,000 parent compounds and in excess of 17,000 reactions*. Used by DMPK scientists across a range of industries, Meteor Nexus adds value in numerous stages of compound and drug discovery. *Meteor Nexus v3.1

Features and benefits Metabolite Identification Meteor s comprehensive knowledge of metabolic transformations ensures structure elucidation of experimentally seen metabolites. Intuitive tools allow filtering of results using various parameters including structure, exact mass and mass defect with the ability to add experimental data to guide predictions. Metabolic Fate Assessment Meteor can swiftly provide predictions for the likely metabolic fate of query compounds. Customisable Reports Transparency Predictions are clearly represented and contain detailed supporting evidence associated with the biotransformations predicted. Expert commentary, including a review of data, mechanistic rationale and explanation of the structure activity relationship are also included. User Control Meteor incorporates three prediction methodologies allowing the option to tailor results as required. With this control, only the most likely metabolic routes for the query compound are predicted whilst the flexibility to spot obscure metabolites is retained. Meteor incorporates a reporting framework that allows (.doc.pdf.xlsx and.sdf) file export. Report templates are fully customisable by the end user.

Features and benefits Reduce Risk in R&D Save time and money by identifying reactive, potentially adduct-forming intermediates and quickly assessing their toxicity through Derek, Sarah or Vitic Nexus. Extensive Metabolism Knowledge Drawing on over 30 years of experience, Lhasa expert scientists implement Meteor biotransformations utilising public and proprietary data ensuring vast coverage of biotransformations. Users can also incorporate their own data into Meteor, thereby generating predictions relevant to their chemical space. Accurate Metabolite Ranking The three methodologies in Meteor rank predicted metabolites by taking into account experimental data and the chemical environment of the site of metabolism, ensuring presentation of the metabolites most likely to be observed experimentally. Identifies the Site of Metabolism The fully integrated SMARTCyp model ranks the most likely sites of metabolism for compounds that are liable to cytochrome P450 mediated metabolism. Early Screen for Toxic Metabolities Using Meteor within the Nexus platform gives direct access to toxicity predictions and data from Derek, Sarah and Vitic within the predicted metabolic tree, improving workflow efficiency.

How Meteor Nexus works In-depth research by Lhasa has resulted in the development of 3 methodologies for assessing the likelihood of a predicted metabolite. The starting point for each methodology is the firing of one of the biotransformations within Meteor s extensive biotransformation dictionary. The level of likelihood of each biotransformation is then calculated by one of the user defined methodologies described below: Rule-based Absolute / Relative Reasoning (The Original Methodology) Rule-based expert system PREDICTION How likely is it that each reaction will occur? Dictionary of biotransformations What reactions can occur? Database of experimental reactions machine learning PREDICTION The original Meteor prediction methodology is a qualitative rule-based approach to assessing likelihood. Biotransformation likelihood is derived from an inherent level of likelihood determined by Lhasa s scientific experts, which is modified by rules based on the lipophilicity of the parent and competing biotransformations. This methodology is ideal for those who wish to have the maximum predictive coverage of biotransformations and to spot obscure metabolites not necessarily identified experimentally. Database of experimental reactions Static Scoring (Occurrence Ratio) Uses a pre-computed score to assess how predictive a biotransformation is, based on experimental data, and orders the predicted metabolites according to this score. This enables you to quickly see which of the metabolites are most likely to be observed experimentally. Site of Metabolism Scoring (SOM) (with Molecular Mass Variance) Builds on the Static Scoring methodology by tailoring the score using experimental data for compounds that match the same biotransformation, have similar molecular weights and are chemically similar around the site of metabolism to the query compound. This enables you to tailor the predictions based on the chemical environment of the site of metabolism delivering more accurate predictions.

When asked why people choose to work with Lhasa Limited, the common responses are: Why choose Lhasa? 1 Over 30 years of experience in developing state-of-the-art in silico prediction and database systems. 3 All science is developed in-house, providing the opportunity to discuss directly with Lhasa expert scientists. 2 Transparency of Lhasa systems allows trust and confidence in the science presented. 4 Software is easy to use and well supported.

Our Products What other software do we produce? Derek Nexus TM An expert rule-based system for the prediction of toxicology. Mirabilis TM A tool for assessing the relative purging of mutagenic impurities. Sarah Nexus TM A statistical-based system for the prediction of mutagenicity. Vitic Nexus TM A chemical database and information management system. Zeneth TM An expert rule-based system for the prediction of degradation pathways. References Judson et al. (2015). Assessing Confidence in Predictions Using Veracity and Utility A Case Study on the Prediction of Mammalian Metabolism by Meteor Nexus, Molecular Informatics, vol. 34, no. 5, pp284-291. http://dx.doi.org/10.1002/minf.201400184 Long, A., (2012), Drug metabolism in silico the knowledge-based expert system approach. Historical perspectives and current strategies., Drug Discovery Today: Technologies, vol. 10 10, no. 1, pp147-153. http://dx.doi.org/10.1016/j.ddtec.2012.10.006 Long et al. (2012). Expert Systems - The Use of Expert Systems in Drug Design-Toxicity and Metabolism, Drug Design Strategies: Quantitative Approaches, 2012, 11, pp279-311. http://dx.doi.org/10.1039/9781849733410-00279 shared knowledge shared progress www.lhasalimited.org For more information, please contact info@lhasalimited.org Reference 01/18